Find Out What it Takes to Sustain & Maximize Your Competitive Advantage in China’s Life Sciences Industry

- NCE discovery, new areas of partnering and investing opportunities
- Cancer, diabetes, STAT, and phenotypic drug discovery
- Partnerships with animal research centers, universities and non-profits
- Clinical data harmonization across countries
- Therapeutic clinical trials in psychiatry and pulmonary fibrosis
- Adaptive designs – from concept to taxonomy to trial examples
- Biologics from development to manufacture

Exclusive Pre-Conference Seminar
Globalization Initiatives of The ZhangJiang Pharma Valley
Regulatory updates, IP, biologics and TCM challenges, and funding sources from Pudong government

www.IBCLifeSciences.com/China
China is now the number one choice for pharmaceutical companies' globalization efforts as seen by the huge number of offshore offices, new joint ventures and collaborations. However, with the growing competition and the financial crisis, how can you sustain your company’s competitive edge in China? Where can you turn to for continued growth and innovation? How can you maximize your shareholders’ return on investment?

IBC’s China 2009 Pharmaceutical R&D Summit offers you the opportunity to hear examples and strategies on innovative R&D, legal and regulatory improvements, as well as new initiatives from the government and industry sectors, including biologics, adaptive designs and others. Learn how to tap into these new areas to sustain and maximize your growth in China.

### Be Informed …
Gain insights into global and local pharma perspectives for the future and learn innovative ideas that you can apply to your own R&D projects.

### Be Heard …
Share your company’s creative business strategy AND offer your experience, expertise and insights to fellow colleagues and potential partners.

### Be Connected …
Attend interactive panel discussions, conference sessions and networking events to stay connected with new and old acquaintances.

---

### Attend This 3-day Event to Gain Insights Into:

- **Innovative Drug Discovery & Development in China** – hear case studies on cancer, diabetes, and more from Shanghai Hengrui; Shenzhen Chipscreen and Shanghai Ambrosia.

- **Licensing to Co-Development Partnerships in R&D** – develop your own operational strategy based on new partnerships and joint venture examples from European and Australian companies, as well as collaborations with academia and non-profit organizations.

- **Clinical Regulatory Affairs** – attend an interactive panel discussion covering data harmonization, challenges in SFDA requirements for IND submissions, expediting NDA approvals, SFDA regulations on FIH trials etc.

- **Therapeutic Clinical Trials** – showcasing current trials by Lundbeck, Novo Nordisk, Shanghai Genomics etc.

- **Adaptive Designs** – attend this mini-workshop for an introduction to the taxonomy of adaptive designs with speakers from Sanofi-Aventis, Merck and US FDA.

- **Biologics Development Update in China** – uncover the challenges and understand the expectations from big and small pharma, presented by Simcere, Epitomics, 3SBio, T Mab, MedImmune, Merck, GSK, Beijing Novo Nordic, ImClone Systems, Shanghai Celgen, Amgen, MediBiotech, PharmaLegacy and more!

- **China as the Innovation Center for Global Pharmaceutical R&D** – showcasing panels on NCE Discovery, New Areas of Partnering and China’s Life Sciences Investments.

---

### Pre-Conference Seminar • Monday April 6, 2009

**Globalization Initiatives of The ZhangJiang Pharma Valley**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>Registration</td>
</tr>
<tr>
<td>1:00</td>
<td>Welcome Address</td>
</tr>
<tr>
<td>1:10</td>
<td><strong>The Biological Industry &amp; Internationalization</strong></td>
</tr>
<tr>
<td></td>
<td>HongGuang Wang, Ph.D., Director, Bio Science Development Office, Ministry of Technology</td>
</tr>
<tr>
<td>1:25</td>
<td><strong>Overview and Vision of ZhangJiang Pharma Valley</strong></td>
</tr>
<tr>
<td>1:45</td>
<td><strong>The International Challenge and Opportunities for TCM Development</strong></td>
</tr>
<tr>
<td></td>
<td>De-an Guo, Ph.D., TCM Modernization Center</td>
</tr>
<tr>
<td>2:05</td>
<td><strong>The Evolution of IP Protection in Biopharmaceutical Industry in China</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker from Pudong Intellectual Property Administration</td>
</tr>
<tr>
<td>2:25</td>
<td>Networking Refreshment Break</td>
</tr>
<tr>
<td>2:45</td>
<td><strong>Panel Discussion:</strong></td>
</tr>
<tr>
<td></td>
<td>Development and Globalization Strategies and Experiences from Small and Medium-sized Biopharmaceutical Companies</td>
</tr>
<tr>
<td></td>
<td>Senior representatives from local and foreign small and medium-sized companies and MNCs</td>
</tr>
<tr>
<td>3:35</td>
<td><strong>The Latest Regulation for Drug Registration</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker from SFDA or Center for Drug Evaluation, SFDA</td>
</tr>
<tr>
<td>3:55</td>
<td><strong>Current Entry-Exit Policy for Biological Products</strong></td>
</tr>
<tr>
<td></td>
<td>Speaker from Pudong Entry-Exit Inspection and Quarantine Bureau</td>
</tr>
<tr>
<td>4:15</td>
<td><strong>Funding Support from the Pudong Government</strong></td>
</tr>
<tr>
<td>5:00</td>
<td>Cocktail Reception</td>
</tr>
</tbody>
</table>

*Simultaneous Translation available for Pre-Conference Seminar only*

---

**To Register:**
Tel: (+65) 6514-3180 • Fax: (+65) 6733-5087 • E-mail: register@ibcasia.com.sg
Main Conference Day One

Tuesday, April 7, 2009

Keynote Plenary Session

8:35 Opening Address by IBC
8:45 Welcome Address

Yiping Li, Ph.D., Shanghai Pudong New District Governor

8:55 Chairperson’s Opening Remarks

Li Chen, Ph.D., Head of Research and Chief Scientific Officer, Roche R&D Center (China) Ltd.

9:00 Restructuring for Innovation: How China Companies Can Learn from Roche’s Global Initiatives

Innovation is at the heart of drug discovery and is measured by the creation of medically differentiated healthcare products for patients around the world. At Roche, we decided to create the first wholly-owned R&D Center for Roche in China in an attempt to drive innovation and our future growth. We came to China to gain access to the talented scientists and to help develop this talent into drug hunters who will contribute important medicines to the Chinese public. This presentation will discuss Roche’s overall strategy for doing innovative drug discovery in China, as well as testing radically different approaches to develop new medicines.

Lee E. Babiss, Ph.D., President and Global Head of Pharma Research, F. Hoffmann-La Roche, Ltd.

9:35 The Developing Pharmaceutical R&D Model in China: What Is Next?

Abstract not available at time of print. Please visit website www.IBCLifeSciences.com/China for updates.

Robert W. Armstrong, Ph.D., Vice President, Global External Research and Development, Eli Lilly and Company

10:10 The Global Partnering Strategy of Merck & Co. Inc.

In a global economy, innovation is distributed worldwide. Merck & Co. Inc. has organized its research model to acknowledge the fact that ideas know no boundaries and to cherish science as an international language. The results of our global partnering efforts in drug discovery and development will be discussed.

Merv Turner, Chief Strategy Officer & Senior Vice President, Worldwide Licensing & External Research, Merck & Co., Inc.

10:45 Grand Opening of Exhibit & Poster Hall and Networking Refreshment Break held in Exhibit & Poster Hall

Sponsored by Osha Liang

China as the Innovation Center for Global Pharmaceutical R&D

11:30 Panel Discussion

NCE Discovery & Development in China

- What are the key advantages (besides cost) of carrying out R&D in China?
- Main hurdles in carrying out NCE R&D in China – potential solutions?
- What will China’s NCE R&D look like in 5 years?
- What will be a healthy ratio of CRO and NCE R&D activities in China?

Panelists:

Sofie Qiao, Ph.D., President & CEO, Lead Therapeutics
Zhengyu Yuan, Ph.D., President & CEO, MicruRx Pharmaceuticals Inc.
Ming Guo, Ph.D., Vice President, Ascenta (Shanghai) R&D Center; Vice President, Pharmaceutical Sciences & Manufacturing, Ascenta Therapeutics, Inc.
Zelin Sheng, Ph.D., Chief Operating Officer, Egret Pharma (Shanghai) Ltd.

12:30 Networking Luncheon in Exhibit & Poster Hall

2:00 Panel Discussion

New and Evolving Areas for Partnering – What Opportunities Does China Present to Global Companies?

- Licensing Chinese rights for regulatory approval and distribution to Chinese companies
- How to form partnerships between innovative early stage company with mature Chinese company who can do clinical to manufacturing
- Chinese companies looking for late-stage development programs to partner with
- Where Chinese companies can use their expertise? – manufacturing, cell line development?
- New opportunities for partnerships in vaccines, diagnostics, medical devices, drug delivery etc.

Panelists:

Mark Lotter, Ph.D., Chief Executive Officer, Novamed Pharmaceuticals, Inc.
Allan (Riting) Liu, Ph.D., Business Development Director, Corporate Technology Center, Shanghai Fosun Pharmaceutical (Group) Co Ltd.
Jia Qian, Ph.D., Deputy General Manager, North China Pharmaceutical Corporation
Sam Liao, Head, Business Development & Licensing, Asia, Novartis Vaccines & Diagnostics, Inc.
Stella Xu, Ph.D., Global Licensing Director, Roche Pharma Partnering Asia
Richard Wang, Ph. D., Director, Strategic Alliance Asia, Innovation Center China, Astra Zeneca

2:50 Panel Discussion

Intellectual Property Issues in Partnering/Licensing

- Compare what’s happening in China vs. US/EU
- Extension of patents in China
- Patent enforcement rights and challenges
- How to uphold secondary patents in Chinese courts?

Panelists:

Lewis Ho, Consultant, Simmons & Simmons
Chyau Liang, Ph.D., Partner, Osha Liang LLP

3:30 Networking Refreshment Break in Exhibit & Poster Hall

Sponsored by bioBAY

Banking on China’s Life Sciences Futures

4:00 Panel Discussion

VC Investments in China: So Many Leads, So Few Deals – Why? Where are the Drug Discovery Innovations and Investments?

Venture Capital interest in life sciences in China has taken off very recently—even five years ago, convincing a U.S.-based VC to invest in China was almost impossible. Since the Wuxi Pharmatech IPO, the TPG investment in ShangPharma and the Charles River acquisition of BioExplorer, interest has skyrocketed, but few deals are actually getting done. There are a lot of lessons to be learned from the history of biotech investing in Europe and the U.S., but few of the current Chinese entrepreneurs or VC’s were involved in those experiences. There are also unique factors in China which many U.S.-based VCs are not factoring in.

Introductory Remarks - Life Sciences Investing in China: Obvious and Not-So-Obvious Influences

Dr Hsu will highlight a few items for VCs and entrepreneurs to think about in planning new Chinese life sciences ventures.

Charles Hsu, Venture Partner, Bay City Capital LLC, USA

Panelists:

Norman Chen, Partner, HealthCare, Fidelity Asia Ventures
Charles Hsu, Venture Partner, Bay City Capital LLC
Yi Shi, Managing Director, Lilly Asian Ventures
Nisa Leung, Partner, Qiming Venture Partners
Carl Firth, Ph.D., MBA, Head of Asia Pacific Healthcare, Investment Banking, Merrill Lynch
Dajun Yang, Ph.D., Partner, Morningside

5:15 “A Taste of Shanghai” Networking Cocktail Reception in Exhibit & Poster Hall

Sponsored by Simmons & Simmons
8:50 Chairperson's Opening Remarks
Guoxin Zhu, Ph.D., Director, Discovery Chemistry Research & Technology, Lilly Research Laboratories Eli Lilly & Company

9:00 Discovery & Development of SHR1020 for Cancer Treatments in China
Structure-modification of SU1248 (SUTENT) has resulted in discovery of 2 series of compounds with equal or better potency than SU1248. The discovery & development of SHR1020 will be discussed as well as its potentials as an affordable new anticancer drug for greater Chinese population beyond the urban areas.
Peng-Choo Tang, Ph.D., Chief Scientific Officer, Shanghai Hengrui Pharmaceutical Co., Ltd.

9:30 Chiglitazar—A Configuration-Restricted PPAR Pan Agonist Currently in Human Trials
T2D type of insulin sensitizer is PPARa agonist and the only treatment so far targeting mechanistically and directly against insulin resistance. Based on the functional importance of each subtype of PPAR, identification of synthetic ligands to simultaneously target multiple PPAR subtypes would be beneficial. Although such efforts have been overshadowed by the discontinuation of several PPARa/γ dual agonists in clinical development, probably due to the safety concerns, it lacks evidence from humans that ligands targeting multiple subtypes would actually cause additive adverse effects derived from the activation of individual PPAR subtypes. This presentation will focus on Chiglitazar, which is a configuration-restricted PPAR pan agonist with weight on PPARa currently under phase IIb trial in China.
Xian-Ping Lu, Ph.D., President and Chief Scientific Officer, Shenzhen Chipscreen Biosciences, Ltd.

10:00 Accelerated Translation from Lead Optimization to Clinical Development: A Critical Overview of Human Microdosing and Exploratory IND (Phase 0) Studies
Traditional Phase 1 clinical development plan could be preceded by Phase 0 that involves early first-in-human (FIH) screening studies with sub-pharmacological or low pharmacologically active doses of one or several novel drug candidates that are difficult to differentiate on the basis of the preclinical lead optimization studies. The most promising compound would be selected for Phase 1 on basis of the human pharmacokinetic and pharmacodynamic data from Phase 0. This presentation will outline the US and EU regulatory guidance for human screening studies and the potential advantages and limitations of this approach. Case studies of using microdoses and single pharmacologically active doses for early decision making in exploratory drug development will also be presented.
Nenad Sarapa, M.D., Senior Director, Johnson & Johnson Pharmaceutical Research and Development

10:30 Networking Refreshment Break in Exhibit & Poster Hall

11:00 Sponsored Presentation
Genotype-correlated Phenotypic Drug Discovery - OncoPanel™
OncoPanel comprises of a compendium of a large panel of human tumor-derived cell lines from different origins with broad genetic heterogeneity and a sensitive High Content Analysis method for comparing proliferation or cytotoxicity across genotypes. We have developed a panel of 240 human cell lines with genetic information available on the genome copy number, mRNA expression data and gene mutation. The media and culture conditions, cell fixation and High Content Analysis are standardized and optimized so that the genetic heterogeneity of the cell line will be responsible for the results obtained. We generate simultaneous data for each compound at 10 concentrations in triplicates resulting in precise IC50/EC50 values for analysis and comparison. Results from a case study will be presented to depict the very robust data quality. Also, data with known inhibitors will be presented using a smaller subset of the cells.
Susan Wang, Ph.D., Technical Director, Pharmacology DM PK, MDS Pharma Services

11:30 Target the STAT Signaling Pathway
STATs (Signal Transduction and Activation of Transcription) are a family of 7 proteins, STAT1, 2, 3, 4, 5A, 5B, and 6. They are critical signal transducers of various cytokines and play important roles in regulating proliferation, differentiation, migration, and survival/death of many types of cells, particularly immune system cells. The STATs are critical for various immune system diseases and cancer. We have developed cell-based assays to identify drug candidates targeting the STATs signaling pathways. Both positive and negative regulators of the STAT pathway have been identified. These regulators are potential drug candidates for treating cancer and inflammation.
Qiang Yu, Ph.D., Chief Executive Officer, Shanghai Ambrosia Pharmaceutical Co. Ltd.

10:00 Comparison of New Drug Application Procedures and Regulations Between USA and China
Differences and similarities between USA and China in new drug application (IND) procedures and regulations will be analyzed in the presentation. Although the IND procedures in USA are more transparent and effective than those in China, the SFDA is improving their regulations to stimulate innovative R&D and ensure drug quality.
Lee Jia, Ph.D., Project Manager, Developmental Therapeutics Program (DCTD), National Cancer Institute/NIH

10:30 Networking Refreshment Break in Exhibit & Poster Hall
12:00 Sponsored Presentation
The Impact of CRO Companies in China NCE R&D
Western pharmaceutical companies are turning more and more to CRO companies in India and China to develop their new drugs. These same CRO companies in China can provide the basic infrastructures for China NCE R&D. A China company does not need to build its in-house capabilities, but instead use the capabilities from CROs to develop a new drug. This talk will summarize the capabilities available in China, and showcase what GenScript can offer in more detail.
Frank L. Zhang, Ph.D., Chief Executive Officer, GenScript Corporation

12:30 Networking Luncheon in Exhibit & Poster Hall

---

**Track I**
Innovative Discovery & Development

12:00 Sponsored Presentation
The Impact of CRO Companies in China NCE R&D

1:00 Chairperson’s Opening Remarks

1:15 Building, Growing & Sustaining a Biotech Business – a European/North American Experience

2:05 Case Study: Strengths, Weaknesses, Opportunities and Threats in Australia-China Partnership

2:55 Sponsored Presentation
Conducting Preclinical Research in China

3:20 Networking Refreshment Break and Last Chance for Exhibit & Poster Viewing

**Collaborations with Academics and Non-Profits**

3:50 The Power of Collaboration: From Butterfly Wings to ALIMTA®

4:15 Perspective in China: Genetic Engineered Mouse for Disease Models

---

**Track II**
Clinical Trials, Safety, Quality & Adaptive Designs

12:30 Networking Luncheon in Exhibit & Poster Hall

---

**Safety & Quality Evaluations**

2:00 Chairperson’s Opening Remarks

2:05 General Statistical Considerations in the Safety Evaluation of Medical Products

2:30 Hypothesis Testing in Early Drug Development – Time for Significant Change

2:55 The Issue of Quality – Ensuring Data Integrity, Quality in Clinical Trials

3:20 Networking Refreshment Break and Last Chance for Exhibit & Poster Viewing

---

**Mini-Workshop: Adaptive Designs**

One of the largest challenges pharmaceutical companies face in bringing new drugs to market is the clinical trial process. Adaptive design allows for modifications to the on-going trial based on the observed data from the trial. It is recognized that adaptive designs can improve the efficiency of clinical research and increase the probability of success.

With the growing need to conduct global clinical trials smarter, one way to make this process more efficiently (and also is currently receiving significant attention from the industry and regulatory agencies) – is adaptive trial design.

Join this mini-workshop to get introduced to the concept and taxonomy of adaptive designs through trial examples; learn case studies and explore the challenges in the implementations of adaptive designs and its implications towards clinical operations in China.

3:50 Adaptive Clinical Trials—Innovation of the Decade in Clinical R&D

- Drug development challenges - increased R&D investment with decreased output
- Why now - New science, technology and statistical method
- Key difference between traditional and adaptive designs
- Ethical and cost advantages of adaptive design
- Risk in clinical execution and regulatory acceptance

Frank Jiang, MD, Ph.D., VP Global R&D, Head China R&D, Sanofi-Aventis

4:15 Biostatistics and Adaptive Trial Design: From Computer Side to Bedside

- A quick overview of Biostatistics
- Adaptation by design: fixed adaptation vs. continuous/dynamic adaptation
- Consideration for Adaptation in Exploratory and Confirmatory Trials
- Hypo & hopes with adaptive design
- How to plan for sample size
- How to control type I errors
- Clinical operation challenges
- Case Studies

Frank Shen, Ph.D., Head, Biometrics, Roche Global Pharma Development Center
BIOLIFE SCIENCES
Thursday, April 9, 2009

Main Conference Day Three

8:50 Chairperson's Opening Remarks
Guo-Liang Yu, Ph.D., President & CEO, Epitomics Inc.

9:00 Antibody technology: where do we go from here?
Progress in therapeutic antibodies parallels the technology advancement in antibody engineering. This presentation will discuss the technological trend in therapeutic antibody discovery and development: 1) Fe-engineering to create therapeutics with more potent biological activities; 2) Glycoengineering to improve the pharmaceutical properties; 3) New sources and formats of antibodies; 4) In silico tools to analyze antibody sequences for humanization and immunogenicity prediction; 5) Alternative antibody expression technologies; and 6) Accessing intracellular and CNS targets
Zhiqiang An, Ph.D., Chief Scientific Officer, Epitomics Inc

9:25 Next Generation Antibody Technology & Beyond
Abstract not available at time of print, please visit www.IBCLifeSciences.com/China for updates.
Herren Wu, Ph.D., Vice President, Head of Antibody Discovery and Protein Engineering, and Global Head of Technology, MedImmune, Inc.

9:50 Current Status and Future of Biologics Development in China
Abstract not available at time of print, please visit www.IBCLifeSciences.com/China for updates.
Xiaojun Yin, Ph.D., Chief Scientific Officer, Sincere Pharmaceutical
Jing Lou, Ph.D., Chief Executive Officer, SBio

10:30 Networking Refreshment Break

Expectation and Perspectives of Multinational Pharmaceutical Companies

11:00 How to Build Internal Capabilities In A Big Pharma For Biologics
Abstract not available at time of print, please visit www.IBCLifeSciences.com/China for updates.
David Shen, Ph.D., Executive Director & Head, Department of Biologics Research, Merck & Co.

11:20 Protein Therapeutics R&D at Novo Nordisk
Baoping Wang, Ph.D., Vice President & Head, Beijing Novo Nordisk Pharmaceuticals Science & Technology Co.

11:40 GSK’s Biologics Development in China
Lixin Li, Ph.D., GlaxoSmithKline, China

12:00 Panel Discussion
The Trends of Biologics Development in China
Speakers form the morning session

12:30 Networking Luncheon

Track I
Innovative Discovery & Development

4:40 Non-Profit Pharma: The Growing Role Of Research Institutes in Drug Discovery and Development
Innovative drug discovery is increasingly challenging with spiraling costs and timelines of product development in the pharmaceutical industry. With a unique business model that interfaces government-funded academic translational research with commercial partnerships, SRI Biosciences develops high quality drug candidates ready for clinical development at greatly reduced risk. Successful public – private partnerships will be show cased as examples of the power of this approach.
Nathan Collins, Ph.D., Executive Director, Drug Discovery, Biosciences Division, SRI International

5:05 AT-Bio. Case Study of Globalization of China’s Drug Development
Combining the drug development capabilities in China with the drug discovery and international business. Management capabilities in Australia to develop small molecule therapeutics for global markets. AT-Bio is an Australian joint venture of the Tianjin Institute for Pharmaceutical Research (TIPR). This presentation will discuss the relationship development, business structure, IP management, regulatory management and opportunities.
Jim Murray, MBA, Chief Executive Officer, AT-Bio Pty Ltd., Australia

5:30 Close of Day Two

Track II
Clinical Trials, Safety, Quality & Adaptive Designs

4:40 Regulatory Reviewer’s Perspective of Adaptive Design
Ning Li, MD, PhD, Team Leader, DBS/OSB/FDA (invited)

5:05 Mini Panel Discussion

5:30 Close of Day Two

Challenges of Biologics Development and Manufacture

2:00 Enhancing Antibody-Based Cancer Therapy By Antibody Combinations and Dual-Targeting Bispecific Antibodies
Antibodies are becoming an important class of antitumor agents, as they have been shown to enhance the efficacy of various therapeutic regimens without significantly increasing systemic toxicity. Further, results from pre-clinical and early clinical studies suggest that combination of antibodies may be more efficacious than each individual antibody alone. Antibody combinations and dual-targeting bispecific antibodies represent promising approaches to more efficacious antitumor therapy.
Zhenping Zhu, M.D., Ph.D., Vice President, Antibody Technology, ImClone Systems Inc.

2:20 Developing A World-Class Mammalian Cell Culture Platform to De-Bottleneck mAb Development
Bottleneck of developing novel antibodies is to produce the first 100g of clinical materials. Currently it takes up to 18 months and costs up to $5 million, which poses significant technical and financial challenges to startup companies. Shanghai Celgen has developed a world-class CHO cell line/culture development platform that can routinely generate 1-5g/L cell culture processes to expedite mab development.
Chris Chen, Ph.D., Chief Operating Officer, Shanghai Celgen Biopharmaceuticals

2:40 Bioanalytical Strategies for Quantifying Monoclonal Antibody Therapeutics in Matrix
Specific, sensitive and robust analytical methods that quantify antibody therapeutics in serum and tissues are critical for the evaluation of drug efficacy and safety in preclinical and clinical stages. Here we introduce our strategies of screening anti-idiotypic antibodies as ELISA reagents, and then developing and validating the assay for PK/Tox study support.
Shaoxiong Wang, Ph.D., Senior Scientist, Translational Sciences, Amgen Inc.

3:00 Vivatuxin - A Successful Story of East West Partnerships to Capture Chinese Growing Antibody Market
Vivatuxin, a radiolabeled TNT chimeric monoclonal antibody, represents the first therapeutic antibody approved by SFDA for the treatment of malignant lung cancer. Clinical trials of Vivatuxin for liver cancer and brain cancer are underway. Experience of the preclinical and clinical development of Vivatuxin will be shared. This is a case study of successful and unique east west collaboration in R&D of novel antibody-based pharmaceuticals.
Dianwen Ju, Ph.D., Chief Executive Officer, MediBiotech, Co. Inc.

3:20 Networking Refreshment Break

3:45 Panel Discussion
Understanding the Regulatory Pathway, IP and Investment Climate for Biologics in China
Panelists:
James J. Zhu, Ph.D., Partner, Perkins Coie LLC; Hongbo B. Lu, Ph.D., Vice President, Senior Research Analyst, Healthcare, Piper Jaffray & Co.; Danny R. H., Ph.D., MBA, Chief Executive Officer, Pharmaxis Limited; Jiwan Qiu, Ph.D., Chief Executive Officer, T-Mab Biotechnology Co. Ltd.; Hongbo B. Lu, Ph.D., Vice President, Senior Research Analyst, Healthcare, Piper Jaffray & Co.

4:45 Close of Conference

Call for Posters
IBC's China 2009 Pharmaceutical R&D Summit is focused on providing the highest level of education through speaker presentations as well as scientific posters. Selected posters are to be published in the proceedings. We invite you to display your research findings at China 2009 Pharmaceutical R&D Summit. Any registered attendee may sign up to present a poster. Posters are accepted until March 6, 2009 or while space lasts. Poster slots fill up quickly so please submit your abstract today at www.IBCLifeSciences.com/China. All abstracts must be submitted online and are subject to review and approval prior acceptance. Registration and payment must be received by March 1, 2009 to be guaranteed a poster space. Poster size is 8” x 4’W.
*Due to limited space for posters, each attendee is limited to one poster, and each company are limited to 2 posters for the event.
Qiming focuses on helping Chinese entrepreneurs gain the advantage they need to build great companies across China in healthcare, consumer, internet, media, cleantech and other sectors. Qiming is a premier venture capital firm located in Shanghai. Qiming investing in high growth opportunities in biotechnology, biopharmaceutical and life sciences. For more information, through Asia in November.

The venture capital organizations of Fidelity Investments, headquartered in Boston, and FIL, headquartered in London, have invested its proprietary capital around the globe for nearly 40 years. The venture capital divisions have invested in more than 1,100 companies. Our clients include many of the world’s leading research-based pharma, biotech, medical device, healthcare companies. Visit www.simmons-simmons.com/lifesciences for more information about Simmons & Simmons, a law firm for Life Sciences. We advise many of the world's leading research-based pharma, biotech, medical device, healthcare companies.

Headquartered in New Jersey, Genscript is the largest biology contract research organization (CRO) for early drug discovery with operation in China, and direct subsidiaries in Europe and Japan. By consolidating its comprehensive lines of drug discovery services into two centers (bio-reagent center and bio-assay center), Genscript offers an innovative sourcing solution to its various pharmaceutical partners with premium quality, ensured fast delivery, and cost effectiveness.

MDS Pharma Services offers pharmacology services to pharmaceutical, biotechnology and medical-device companies. We offer an encompassing selection of biochemical, cellular/ functional, DMPK and in vivo assays for use in identifying lead compounds, profiling for selectivity, and testing the potential for adverse events. Specialized areas include CNS, bone, oncology, immunology, and anti-infective.

Merrck & Co, Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merrck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. During 2006, Merrck launched five new products – Gardasil, Januvia, Zostavax, Zolnita and RotaTeq. We also signed S3 strategic acquisition and alliance agreements which complement our internal research and development efforts and enhance our pipeline. In 2006, worldwide sales were $22.6 billion. Currently, Merrck is focusing its resources on finding new treatments for: Alzheimer’s disease, atherosclerosis, cardiovascular disease, diabetes, novel vaccines, obesity, cancer, pain, and sleep disorders.

Bronze Sponsor

Excel

The Leading CRO in China
Excel PharmaStudies (www.excel-cro.com) is the leading full service clinical research organization in China. Our main office is in Beijing and we have branch operations in thirteen other large cities. In addition, we have limited operations in Korea, Hong Kong, Thailand, Taiwan, and Singapore. In the past few years, Excel has been involved in about 170 international and local phase I to IV trials in 25 cities at about 140 hospitals, and including about 150,000 patients. Excel has strong medical, regulatory and data management teams. Our clients include many of the top 40 international pharmaceutical companies.

Presentation Sponsor

GenScript

Headquartered in New Jersey, Genscript is the largest biology contract research organization (CRO) for early drug discovery with operation in China, and direct subsidiaries in Europe and Japan. By consolidating its comprehensive lines of drug discovery services into two centers (bio-reagent center and bio-assay center), Genscript offers an innovative sourcing solution to its various pharmaceutical partners with premium quality, ensured fast delivery, and cost effectiveness.

MDS Pharma Services offers pharmacology services to pharmaceutical, biotechnology and medical-device companies. We offer an encompassing selection of biochemical, cellular/ functional, DMPK and in vivo assays for use in identifying lead compounds, profiling for selectivity, and testing the potential for adverse events. Specialized areas include CNS, bone, oncology, immunology, and anti-infective.

Cocktail Reception Co-Sponsors

Simmons & Simmons

Simmons & Simmons is a leading international law firm with an international network of 20 offices, including Shanghai and Hong Kong. We are recognised worldwide as a pre-eminent law firm for Life Sciences. We advise many of the world’s leading research-based pharmaceutical, biotech, medical device, healthcare companies. Visit www.simmons-simmons.com/lifesciences for further information and to receive our regular Life Sciences international newsletter.

The venture capital organizations of Fidelity Investments, headquartered in Boston, and FIL, headquartered in London, have invested its proprietary capital around the globe for nearly 40 years. Fidelity Asia Ventures, with offices in Hong Kong, Beijing and Shanghai, invests in high-quality, high-growth information technology and healthcare sectors primarily in China and throughout Asia. Fidelity Biosciences, based in Cambridge, Mass., focuses on high potential opportunities in biotechnology, biopharmaceutical and life sciences. For more information, visit www.fidelitybiosciences.com or www.fidelityasiaventures.com.

Lanyard Sponsor

Qiming is a premier venture capital firm located in Shanghai. Qiming investing in high growth companies across China in healthcare, consumer, internet, media, cleantech and other sectors. Qiming focuses on helping Chinese entrepreneurs gain the advantage they need to build great companies and achieve lasting success.

Exhibitors (as of December 1, 2008)

Interested in Sponsoring/Exhibiting at China 2009 Pharmaceutical R&D Summit?

Please contact

Asia-Pacific Sales Contact: Wendy Wong, Tel: +65 6835 5126
E-mail: wendy.wong@ibcasia.com.sg

U.S. & European Sales Contact: Sherry Johnson, Tel: +1-508-614-1451
E-mail: sjohnson@ibcusd.com

About the Organizer

This event is brought to you by the organizers of Drug Discovery and Development of Innovative Therapeutics World Congress in Boston and Japan, IBC Life Sciences, an informa business. Other informa businesses include: Datamonitor, MedTRACK, SCRIP and Pharmajournals. www.IBCLifeSciences.com and www.informa.com

Co-Organizers

Making Hotel Reservations

Special room rates have been contracted with the Grand Hyatt Shanghai for IBC’s delegation. To take advantage of this special rate, please visit the conference website at www.IBCLifeSciences.com/China, select Pricing & Venue link to download the reservation form and fax to the hotel directly before March 6, 2009. For questions on conference venue and hotel reservations, please contact Kerina Chua at kerina.chua@ibcasia.com.sg

Travel/Visa Information

PLEASE NOTE: Visas are required for some nationalities to travel to China for this conference. Please contact your travel agent and/or the Chinese Consulate/Embassy in your country for exact details and visa application procedures as soon as possible. Visa processing times can vary.

Team Discounts

Register 3 at the Standard Rate, and the 4th goes FREE! Save up to US$1899. When 3 members from the same company register and pay for the conference at the same rate, the fourth attends for FREE. This discount is valid only based on the same standard rate (after March 6, 2009). For more information on the team discount and to register your team, please contact customer service at register@ibcasia.com.sg

Supporting Organizers

Media Partners

www.IBCLifeSciences.com/China for up-to-date information on this event
4th International Conference & Exhibition

China 2009
Pharmaceutical R&D Summit

April 7-9, 2009 • Grand Hyatt Hotel • Shanghai, China

SAPA Members Receive 20% Off the Standard Conference Rate
Use Priority Code IR9163SAPABROCH

5 EASY WAYS TO REGISTER

Mail: the attached registration form with your cheque to
IBC Asia (S) Pte Ltd,
No. 1 Grange Road,
#08-02 Orchard Building,
Singapore 239693.

Customer Service Hotline: (65) 6514 3180

Fax: (65) 6733 5087
(65) 6736 4312

E-Mail: register@ibcasia.com.sg
Web: www.IBCLifeSciences.com/China

RESERVE YOUR PLACE TODAY!

☐ Yes! I/We will attend China 2009 Pharmaceutical R&D Summit

1st delegate
Name: Dr/Mr/Ms ____________________________
E-Mail ____________________________
Job Title ____________________________
Mobile no ____________________________
Department ____________________________
Company ____________________________
Address ____________________________
Post Code ____________________________
Tel ____________________________

1st delegate Name & Title of Approving Manager ____________________________
Main Business/Activity ____________________________
Name & Title of Training Manager ____________________________
Name & Title of Approving Manager ____________________________
Main Business/Activity ____________________________
Name & Title of Training Manager ____________________________
Please tick: ☐ I enclose my Cheque/Draft payable to IBC Asia (S) Pte Ltd

Card Holder _________________________________________________________
Signature _________________________________________________________
Expire Date _________________________________________________________

I cannot attend this event but ☐ I would like to purchase the conference documentation @ USD399
☐ Please put me on your mailing list.

Registration Fees
Standard Rate
Your Special Rate – 20% Off

<table>
<thead>
<tr>
<th>Event</th>
<th>USD</th>
<th>RMB*</th>
<th>USD</th>
<th>RMB*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main Conference (April 7-9)</td>
<td>1899</td>
<td>1519</td>
<td>10500</td>
<td>8400</td>
</tr>
<tr>
<td>China-based Companies</td>
<td>1099</td>
<td>879</td>
<td>1099</td>
<td>879</td>
</tr>
<tr>
<td>International Academic/Gov</td>
<td>5800</td>
<td>4640</td>
<td>5800</td>
<td>4640</td>
</tr>
</tbody>
</table>

Pre-Conference Seminar Add-On (April 6)
☐ Yes, sign me up. Free for first 100 persons who register for Main Conference. Late registrants will be put on waitlist and notified when space becomes available.

* RMB rates are inclusive of 5.5% Sales Tax.
All rates include luncheon, refreshment and complete set of documentation. It does not include the cost of accommodation and travel.

CANCELLATIONS/ SUBSTITUTIONS:
Should you be unable to attend, a substitute delegate is welcome at no extra charge. Cancellations must be received in writing at least 10 business days before the start of the event, to receive a refund less 10% processing fee per registration. The company regrets that no refund will be made for cancellations received less than ten days prior to the event. IBC reserves the right to cancel or alter the content and timing of the programme or the identity of the speakers for reasons beyond its control and will NOT be held accountable for any costs incurred by the participants. Speakers are subject to change without prior notification.

Payments in USD
Payments in US$ bank draft/ cheque or telegraphic transfer must be made to:
IBC Asia (S) Pte Ltd
A/C No: 260-45 7866-178
The HONGKong and Shanghai Banking Corporation Limited
21 Collyer Quay,
HSBC Building
Singapore 049320

Payments in RMB
Payments in RMB bank draft/ cheque or telegraphic transfer must be made to:
IBC CONFERENCES AND EVENT MANAGEMENT SERVICES
(SHANGHAI) CO., LTD.
Account No. 722-031103-001
Beneficiary Bank: HSBC Bank (China) Company Limited
Bank Address: No.1000 Lujiazui Ring Road, Pudong, Shanghai 200120 R.P.China

DATA PROTECTION:
The personal information entered during your registration/ order, or provided by you, will be held on a database and may be shared with companies in the Informa Group in the UK and internationally. Sometimes your details may be obtained from or shared with external companies for marketing purposes. If you do not wish your details to be used for this purpose, please contact the Database Manager Catherine Shen on catherine.shen@ibcasia.com.sg. Ph: +65 6835 5141 or Fax: +65 6734 4053.

Important Note
Please quote the name of the delegate and event title on the remittance advice when remitting payment. Bank charges are to be deducted from participating organisations own accounts.
Attendance will only be permitted upon receipt of full payment. Participants wishing to register at the door are responsible to ensure all details are as published. IBC Asia will not be responsible for any event re-scheduled or cancelled.

Venue & Hotel Information
Grand Hyatt Shanghai
Jin Mao Tower
88 Century Boulevard
Pudong, Shanghai 200121
People’s Republic of China
Tel: +86-21-5049-1234
Fax: +86-21-5049-8381

Venue:
Grand Hyatt Shanghai
Jin Mao Tower
88 Century Boulevard
Pudong, Shanghai 200121
People’s Republic of China
Tel: +86-21-5049-1234
Fax: +86-21-5049-8381

General Information

Venue & Hotel Information
Grand Hyatt Shanghai
Jin Mao Tower
88 Century Boulevard
Pudong, Shanghai 200121
People’s Republic of China
Tel: +86-21-5049-1234
Fax: +86-21-5049-8381

Venue:
Grand Hyatt Shanghai
Jin Mao Tower
88 Century Boulevard
Pudong, Shanghai 200121
People’s Republic of China
Tel: +86-21-5049-1234
Fax: +86-21-5049-8381

General Information